Experimental gene therapies like AMT‑130 lower toxic huntingtin protein and significantly slow Huntington’s disease, offering ...

Join the ELRIG conference to hear from experts on cell and gene therapy. Discover advancements shaping the future of medicine.

ELRIG, a not-for-profit, volunteer-led organisation dedicated to the global drug discovery community, today announced the ...

How to tell if pharma companies’ NC promises are Trump tariff dodges, legit or both? Plus, the EPA wants to adopt out RTP ...

Live Science's health channel editor makes predictions about the medical breakthroughs and public health shifts to come in 2026. When you purchase through links on our site, we may earn an affiliate ...

Ultragenyx Pharmaceutical (RARE) has completed the rolling submission of its U.S. marketing application for its gene therapy candidate DTX401 for a rare disorder called Glycogen Storage Disease Type ...

For decades, restoring sight after severe eye damage sat firmly in the realm of science fiction. Now a wave of converging advances, from gene editing and stem cells to microchips and laser-based ...

The Company expects to provide a regulatory update after the receipt of official meeting minutes.

Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Jan. 2, 2026 /PRNewswire/ -- Equity Insider News Commentary – The gene therapy market is surging toward $36.55 billion by 2032, powered by ...

When gene therapy was first proposed in the 1970s, the idea seemed straightforward but revolutionary: replacing defective genes with functional ones to cure a disease. But over the decades, this ...

(RTTNews) - Ultragenyx Pharmaceutical Inc. (RARE) announced that it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration for DTX401 ...